
Cytosorbents Corporation: updates and filings
Price
$4.37
November 18, 2026
What Ploutos Investor adds for Cytosorbents
Part of Ploutos Investor, €9.99 a month
- The full history: 15 fiscal years, from 2011
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 43% since Aug 6, 2026, when the 10-Q these figures come from was filed ($7.98 then, $4.52 on Nov 17, 2026). The figures date from before that move.10-Q
- The share price was recently adjusted for a split or a spin-off that the company's last filing does not include yet. Market value, P/E, yields and the other figures measured against the price would mix the new shares with the old figures, so we leave them out until the next filing.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
November 2026
September 2026
August 2026
July 2026
May 2026
April 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 17, 2026Notice that the quarterly report will be filed lateFormNT 10-Q
- Nov 12, 2026Results of operationsForm8-K
- Sep 23, 2026Regulation FD disclosure, other material eventsForm8-K
- Sep 8, 2026Amended articles or bylawsForm8-K
- Aug 14, 2026Shareholder voteForm8-K
- Aug 7, 2026Regulation FD disclosureForm8-K
- Aug 6, 2026Results of operationsForm8-K
- Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jul 6, 2026Delisting noticeForm8-K
- Jun 25, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Jun 25, 2026Additional annual meeting materialFormDEFA14A
- Jun 25, 2026Annual meeting proxy statementFormDEF 14A
- Jun 25, 2026Regulation FD disclosureForm8-K
- Jun 11, 2026Preliminary proxy statementFormPRE 14A
- May 13, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 13, 2026Results of operationsForm8-K
- Apr 15, 2026Annual report (amendment)for the period to Dec 31, 2025Form10-K/A
- Apr 2, 2026Delisting noticeForm8-K
- Mar 30, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Mar 25, 2026Results of operations, Regulation FD disclosureForm8-K
- Feb 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 13, 2025Results of operationsForm8-K
- Nov 13, 2025Quarterly reportfor the period to Sep 30, 2025Form10-Q
- Oct 3, 2025Delisting noticeForm8-K
- Sep 16, 2025Regulation FD disclosure, other material eventsForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 17, 2026 | NT 10-Q | Notice that the quarterly report will be filed late | Document |
| Nov 12, 2026 | 8-K | Results of operations | Document |
| Sep 23, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Sep 8, 2026 | 8-K | Amended articles or bylaws | Document |
| Aug 14, 2026 | 8-K | Shareholder vote | Document |
| Aug 7, 2026 | 8-K | Regulation FD disclosure | Document |
| Aug 6, 2026 | 8-K | Results of operations | Document |
| Aug 6, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jul 6, 2026 | 8-K | Delisting notice | Document |
| Jun 25, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Jun 25, 2026 | DEFA14A | Additional annual meeting material | Document |
| Jun 25, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Jun 25, 2026 | 8-K | Regulation FD disclosure | Document |
| Jun 11, 2026 | PRE 14A | Preliminary proxy statement | Document |
| May 13, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 13, 2026 | 8-K | Results of operations | Document |
| Apr 15, 2026 | 10-K/A | Annual report (amendment)for the period to Dec 31, 2025 | Document |
| Apr 2, 2026 | 8-K | Delisting notice | Document |
| Mar 30, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Mar 25, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Feb 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 13, 2025 | 8-K | Results of operations | Document |
| Nov 13, 2025 | 10-Q | Quarterly reportfor the period to Sep 30, 2025 | Document |
| Oct 3, 2025 | 8-K | Delisting notice | Document |
| Sep 16, 2025 | 8-K | Regulation FD disclosure, other material events | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Mar 29, 2004.
The full analysis
What do Cytosorbents's filings show?
The filings are where every one of Cytosorbents's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.